During the last thirty years we have witnessed sweeping changes in healthcare worldwide, including new and expensive biomedical technologies, an increasingly powerful and influential pharmaceutical industry, steadily increasing healthcare costs in industrialized nations, and new threats to medical professionalism. The essays collected in this book concern costs and profits in relation to just healthcare, the often controversial practices of pharmaceutical companies, and corruption in the professional practice of medicine. Leading experts discuss justice in relation to business-friendly strategies in the delivery of healthcare, access to life-saving drugs, the ethics of pharmaceutical company marketing practices, exploitation in drug trials, and undue industry influence over medicine. They offer guidance regarding the ethical delivery of healthcare products and services by profit-seeking organizations operating in a global marketplace, and recommend pragmatic solutions to enhance organizational integrity and curb medical corruption in the interest of patient welfare.

DENIS G. ARNOLD is the Jule and Marguerite Surtman Distinguished Scholar in Business Ethics at Belk College of Business, University of North Carolina, Charlotte. Formerly he was Associate Professor of Philosophy and Director of the Center for Applied and Professional Ethics at the University of Tennessee at Knoxville. He is author of The Ethics of Global Business (2009) and co-editor of Ethical Theory and Business, 8th Edition (2009) and Rising Above Sweatshops: Innovative Approaches to Global Labor Challenges (2003).
ETHICS AND THE BUSINESS OF BIOMEDICINE

EDITED BY
DENIS G. ARNOLD

University of North Carolina at Charlotte
### Contents

- **List of figures**  
  page vii
- **List of contributors**  
  viii
- **Acknowledgements**  
  x

#### Introduction

1. Medicine and the market  
   *Daniel Callahan*  
   page 20

2. Broken promises: do business-friendly strategies frustrate just healthcare?  
   *Norman Daniels*  
   page 35

3. Are patents an efficient and internationally fair means of funding research & development for new medicines?  
   *Paul T. Menzel*  
   page 62

4. The exploitation of the economically disadvantaged in pharmaceutical research  
   *Tom L. Beauchamp*  
   page 83

5. The dangers of detailing: how pharmaceutical marketing threatens healthcare  
   *Jason E. Hubbard*  
   page 103

6. The ethics of direct-to-consumer pharmaceutical advertising  
   *Denis G. Arnold*  
   page 131

7. Industry-funded bioethics and the limits of disclosure  
   *Carl Elliott*  
   page 150

8. Two cheers for the pharmaceutical industry  
   *Richard T. De George*  
   page 169
Contents

9 The third face of medicine: ethics, business and challenges to professionalism
   Mary Rorty, Patricia Werhane, and Ann Mills 198

10 Theoretical foundations for organizational ethics: developing norms for a new kind of healthcare
    George Khushf 220

11 A crisis in medical professionalism: time for Flexner II
    Daniel Wikler 249

Bibliography 260
Index 283
Figures

9.1 Standard stakeholder map \textit{page 208}
9.2 Prioritized stakeholder map \textit{210}
9.3 Organizational ethics model \textit{213}
**Contributors**

Denis G. Arnold is the Jule and Marguerite Surtman Distinguished Scholar in Business Ethics at the University of North Carolina at Charlotte.

Tom L. Beauchamp is Professor of Philosophy and a Senior Research Scholar at the Kennedy Institute of Ethics at Georgetown University.

Daniel Callahan is a Co-Founder and Director of International Programs at the Hastings Center, Senior Research Fellow in the Department of Philosophy at Yale University, and Senior Lecturer at Harvard Medical School.

Norman Daniels is Mary B. Saltonstall Professor and Professor of Ethics and Population Health at Harvard University.

Richard T. de George is University Distinguished Professor of Philosophy, of Russian and East European Studies, and of Business Administration, and Co-Director of the International Center for Ethics in Business at the University of Kansas.

Carl Elliott is Professor in the Center for Bioethics, Professor of Pediatrics, and Professor of Philosophy at the University of Minnesota, Twin Cities.

Jason Hubbard is a doctoral student in philosophy and an M.B.A. student at the University of Tennessee at Knoxville.

Paul T. Menzel is Provost Emeritus and Professor of Philosophy Emeritus at Pacific Lutheran University.

George Khushf is Associate Professor of Philosophy and Humanities Director at the Center for Bioethics at the University of South Carolina.
List of contributors

ANN E. MILLS is Associate Professor at the Center for Biomedical Ethics, Associate Professor of Medical Education, and Co-Director of the Program in Ethics and Policy in Health Care at the University of Virginia.

MARY V. RORTY is a Faculty Associate at the Center for Biomedical Ethics at Stanford University.

PATRICIA H. WERHANE is the Wicklander Chair of Business Ethics and Director of the Institute for Business and Professional Ethics at DePaul University and Peter and Adeline Ruffin Professor of Business Ethics and Senior Fellow at of the Olsson Center for Applied Ethics in the Darden School at the University of Virginia.

DANIEL WIKLER is Mary B. Saltonstall Professor and Professor of Ethics and Population Health at Harvard University.
The papers collected in this volume derive from a conference sponsored by the Center for Applied and Professional Ethics and the Department of Philosophy at the University of Tennessee. This conference brought together in Knoxville leading bioethicists and business ethicists to discuss issues such as costs and profits in relation to just healthcare, the influence of industry over the practice of medicine and over bioethics, the obligations of pharmaceutical companies to citizens of developing nations, and related themes. In addition to the contributors to this volume, I am grateful to many conference participants for their intellectual contributions. Special thanks are due to Alfred Beasley, Norman Bowie, George Brenkert, Glenn Graber, John Hardwig, E. Haavi Morreim, Gary Pulsinelli, Charlie Reynolds, Michael Stahl, and Laurie Zoloth.

The conference received the generous support of many academic units at Tennessee including the College of Arts and Sciences, the College of Business, the Office of the Chancellor, the Office of Research, the Law School, and the Baker Center for Public Policy. Special thanks in this regard are due to John Hardwig, Bruce Bursten, and Jan Williams. I am grateful to Ann Beardsley and Susan Williams for their capable administrative support.

Many thanks also to the students in my doctoral seminar on the topic of this volume for their penetrating questions and excellent discussion of these issues. Thanks in particular to Todd Johnson and Tom Harter for their help with the book. Special thanks to Jason Hubbard for his excellent research assistance and cheerful embrace of every assigned task. Hilary Gaskin at Cambridge was an early and enthusiastic supporter of this project. Her patience and dedication to the highest standards of publishing are much appreciated. For their love, support, and patience with this project I am especially grateful to Sara Arnold, M.D., and to Skye.